ProKidney presents rilparencel mechanism-of-action findings in advanced kidney disease
PROK•ProKidney expects Phase 3 PROACT 1 enrollment to exceed 500 patients, with topline eGFR slope results expected in Q2 2027. The company says translational studies suggest rilparencel reduces oxidative damage and inflammatory signaling while supporting vascular integrity.
1. Trial timeline and findings
ProKidney expects PROACT 1 enrollment to exceed 500 patients, up from 470, with completion targeted for Q1 2027. Topline rilparencel eGFR slope results are expected in Q2 2027, based on an efficacy analysis expected to include approximately 320 patients. The company targets a biologics license application submission in Q1 2028 and anticipates accelerated approval and commercial launch in the first half of 2029; confirmatory endpoint results supporting full approval are expected in the second half of 2029.
2. Mechanism studies
Translational studies suggest rilparencel reduces oxidative damage and inflammatory signaling while supporting vascular integrity under chronic kidney disease-relevant conditions.
